Debt to EBITDA ratio Analysis of MoonLake Immunotherapeutics - Deep Dive
Birds's Eye
Fundamentals
Fundamentals
Technicals
MovingAverage
Candlestick
PivotPointDebt to EBITDA of MLTX
Dec-23-26.23Very Poor Debt to EBITDA | Dec-22-0.0031Very Poor Debt to EBITDA | Growth-852353.32% |
Debt to EBITDA Analysis of MoonLake Immunotherapeutics
| Debt to EBITDA Ratio of MLTX drastically fell by -852353.32 % this year. |
Other Debt to EBITDA Related Info of MLTX that may interest you.
MoonLake Immunotherapeutics Overview
| Code | Price | Previous Price | Price Change | Sector |
|---|---|---|---|---|
| MLTX | 40.66 | 41.04 | 0.926 % | Biotechnology |
Defination of Debt to EBITDA
The Debt to EBITDA Ratio is a solvency metric that measures the company's ability to meet its debt obligations by earnings before covering its interest, taxes, depreciation, and amortization. more ..
Debt to EBITDA Related Ratios
| CashFlowFromOperationToDebt | DebtToCapital | EVToEBITDA |
Tsr Stability Index
| Mild Stability | |
FY - Historical Debt to EBITDA of MoonLake Immunotherapeutics
| Period | Dec-23 | Dec-22 | Dec-21 | Dec-20 |
|---|---|---|---|---|
| Debt to EBITDA | -26.23 | -0.0031 | -3.31 | -0.549 |
| Change | -852353.32 % | 99.91 % | -502.21 % |
FY Chart of Debt to EBITDA of MoonLake Immunotherapeutics
Note : All Data Generated at the End of Trading Hours (EOD Data)